Cumberland reports ifetroban safety data in Phase 2a trial

Cumberland Pharmaceuticals Inc. released top-line results from its Phase 2a ASSIST-SSc trial on October 23, 2026, evaluating oral ifetroban for patients with systemic sclerosis. The company stated that these results support the safety and tolerability of ifetroban in this rare disease population.

The development was disclosed via a Form 8-K filed with the U.S. Securities and Exchange Commission, with the report date set for October 23, 2026. Cumberland Pharmaceuticals Inc., headquartered in Nashville, Tennessee, is incorporated in Tennessee and listed on the NASDAQ Global Select Market under the ticker CPIX. John Hamm, the company's Chief Financial Officer, signed the current report on behalf of the registrant.

The 8-K filing references a press release dated October 23, 2026, which is furnished as Exhibit 99.1. The document specifies that the trial evaluated oral ifetroban, a drug candidate, specifically within the context of systemic sclerosis. No efficacy metrics, statistical significance levels, or adverse event rates were detailed in the 8-K text itself; the filing limited its description to the support for safety and tolerability. The company did not indicate whether it is an emerging growth company or if it has elected to use the extended transition period for complying with new or revised financial accounting standards.

The filing was submitted pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934. Cumberland Pharmaceuticals Inc. did not check any boxes indicating that the filing was intended to simultaneously satisfy obligations under Rule 425, Rule 14a-12, Rule 14d-2(b), or Rule 13e-4(c) of the Exchange Act. The company's principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203, and its telephone number is (615) 255-0068. The Commission File Number for Cumberland Pharmaceuticals Inc. is 001-33637, and its I.R.S. Employer Identification Number is 62-1765329.